Trial site
Dijklander Ziekenhuis
Hoorn Nh, 1624 NP, NetherlandsNot linked to an institution yet
- 16running trials
- 5closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 25 trials
- Phase 44 trials
- Phase 1/21 trial
- Status
- Active, not recruiting7 trials
- Recruiting7 trials
- Completed5 trials
- Not yet recruiting2 trials
- Lead sponsor
- Amsterdam UMC Stichting2 trials
- European Myeloma Network B.V.2 trials
- Genmab2 trials
- Merck Sharp & Dohme LLC2 trials
- Stichting Amsterdam UMC2 trials
- and 10 more
Running trials
Recruiting
ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis
2026-526167-38-00· Phase 4· Amsterdam UMC Stichting· Source
Not yet recruiting
Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma
2026-526101-15-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Not yet recruiting
Tapering optimisation with placebo-based mechanisms in rheumatoid arthritis: the TOP-RA trial
2025-524593-42-00· Phase 4· Universiteit Leiden· Source
Not yet recruiting
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· Phase 3· The Netherlands Cancer Institute· Source
Recruiting
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
NCT07188025· Phase 3· Erasmus Medical Center· Source
Recruiting
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)
2024-519354-36-00· Phase 4· Amsterdam UMC Stichting· Source
Recruiting
Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early-stage NSCLC: the DIRECT-trial
2024-516580-87-00· Phase 1/2· Stichting Amsterdam UMC· Source
Recruiting
Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort
NCT04897854· Phase 3· Amsterdam UMC· Source
Active, not recruiting
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
NCT06189833· Phase 2· European Myeloma Network B.V.· Source
Active, not recruiting
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· Phase 3· Genmab· Source
Active, not recruiting
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066· Phase 3· Genmab· Source
Active, not recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797· Phase 3· European Myeloma Network B.V.· Source
Active, not recruiting
HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements
NCT03620578· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)· Source
Active, not recruiting
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
NCT01898117· Phase 2· The Netherlands Cancer Institute· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error